Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-dose E 2 /progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple-cohort study. Setting Clinics. Patient(s) Premenopausal women with fibroids and heavy menstrual bleeding (menstrual blood loss [MBL] >80 mL per cycle). Intervention(s) Three months' treatment with elagolix alone: 100 mg twice daily (BID), 200 mg BID, 300 mg BID, 400 mg once daily (QD), or 600 mg QD (all but the 600 mg QD arm were placebo controlled); or elagolix plus add-back therapy: 200 mg BID plus continuous low-dose E 2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E 2 1 mg continuously and cyclical P 200 mg. Main Outcome Measure(s) Least-squares mean percentage change in MBL; adverse events (AEs). Result(s) Mean age was 41.8 years; 73.8% were black; mean baseline MBL was 267 mL. Of randomized women (elagolix alone, n=160; placebo, n=50; elagolix with add-back therapy, n=61), 228 of 271 completed the 3-month treatment period. The MBL percentage change from baseline to last 28 days was significantly greater with elagolix alone (range, −72% to −98%; dose-dependent reduction was highest with 300 mg BID) vs. placebo (range, −8% to −41%); mean percentage changes with add-back regimens were −80% to −85%. Overall AEs were dose independent (elagolix alone, 70.0%–81.3%) but lower with placebo (56.0%) and add-back regimens (55.6%–70.6%). Hot flush was the most common AE (elagolix alone, 45.5%–62.5%; placebo, 12.0%; add-back regimens, 18.5%–26.5%). Conclusion(s) Elagolix significantly reduced heavy menstrual bleeding in women with fibroids. Low-dose add-back regimens substantially reduced flushing. Clinical Trial Registration Number NCT01441635.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bulun, S. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1209993 · Cited by 703
Spies, J. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(01)01702-1 · Cited by 647
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Carr, B., Dmowski, W. P., O’Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014) · Reproductive Sciences · doi:10.1177/1933719114549848 · Cited by 114
Research works printed but not linked: 33
- Baird, 2003, High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence, Am J Obstet Gynecol, 188, 100, 10.1067/mob.2003.99 · DOI · Paper page
- Carlson, 1993, Indications for hysterectomy, N Engl J Med, 328, 856, 10.1056/NEJM199303253281207 · DOI · Paper page
- Stewart, 2001, Uterine fibroids, Lancet, 357, 293, 10.1016/S0140-6736(00)03622-9 · DOI · Paper page
- Wright, 2013, Nationwide trends in the performance of inpatient hysterectomy in the United States, Obstet Gynecol, 122, 233, 10.1097/AOG.0b013e318299a6cf · DOI · Paper page
- Cardozo, 2012, The estimated annual cost of uterine leiomyomata in the United States, Am J Obstet Gynecol, 206, 211, 10.1016/j.ajog.2011.12.002 · DOI · Paper page
- Soliman, 2015, The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013, Am J Obstet Gynecol, 213, 141, 10.1016/j.ajog.2015.03.019 · DOI
- Laughlin, 2011, Uterine leiomyomas: individualizing the approach to a heterogeneous condition, Obstet Gynecol, 117, 396, 10.1097/AOG.0b013e31820780e3 · doi:10.1097/aog.0b013e31820780e3
- Maybin, 2016, Medical management of heavy menstrual bleeding, Womens Health (Lond), 12, 27, 10.2217/whe.15.100 · DOI
- Chabbert-Buffet, 2005, Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications, Hum Reprod Update, 11, 293, 10.1093/humupd/dmi002 · DOI · Paper page
- Donnez, 2012, Ulipristal acetate versus placebo for fibroid treatment before surgery, N Engl J Med, 366, 409, 10.1056/NEJMoa1103182 · DOI · Paper page
- Donnez, 2012, Ulipristal acetate versus leuprolide acetate for uterine fibroids, N Engl J Med, 366, 421, 10.1056/NEJMoa1103180 · DOI · Paper page
- Donnez, 2014, Long-term treatment of uterine fibroids with ulipristal acetate, Fertil Steril, 101, 1565, 10.1016/j.fertnstert.2014.02.008 · DOI · Paper page
- Struthers, 2009, Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix, J Clin Endocrinol Metab, 94, 545, 10.1210/jc.2008-1695 · DOI · Paper page
- Ng, 2017, Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women, J Clin Endocrinol Metab, 102, 1683, 10.1210/jc.2016-3845 · DOI · Paper page
- Diamond, 2014, Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study, Reprod Sci, 21, 363, 10.1177/1933719113497292 · DOI
- Carr, 2013, Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study, J Endometr Pelvic Pain Disord, 5, 105, 10.5301/je.5000157 · DOI · Paper page
- Ács, 2015, Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study, J Endometr Pelvic Pain Disord, 7, 56, 10.5301/je.5000211 · DOI · Paper page
- Hale, 2010, Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and late-reproductive age and the menopausal transition, Obstet Gynecol, 115, 249, 10.1097/AOG.0b013e3181ca4b3a · DOI
- Hallberg, 1966, Menstrual blood loss–a population study. Variation at different ages and attempts to define normality, Acta Obstet Gynecol Scand, 45, 320, 10.3109/00016346609158455 · DOI · Paper page
- Mawet, 2014, Impact of a new levonorgestrel intrauterine system, Levosert, on heavy menstrual bleeding: results of a one-year randomised controlled trial, Eur J Contracept Reprod Health Care, 19, 169, 10.3109/13625187.2014.894184 · DOI
- Hallberg, 1964, Determination of menstrual blood loss, Scand J Clin Lab Invest, 16, 244, 10.3109/00365516409060511 · doi:10.3109/00365516409060511 · Paper page
- Coyne, 2017, Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire, Curr Med Res Opin, 33, 193, 10.1080/03007995.2016.1248382 · DOI
- Mansfield, 2004, Validating a pencil-and-paper measure of perimenopausal menstrual blood loss, Womens Health Issues, 14, 242, 10.1016/j.whi.2004.07.005 · DOI
- Laughlin, 2010, New directions in the epidemiology of uterine fibroids, Semin Reprod Med, 28, 204, 10.1055/s-0030-1251477 · DOI · Paper page
- Eltoukhi, 2014, The health disparities of uterine fibroid tumors for African American women: a public health issue, Am J Obstet Gynecol, 210, 194, 10.1016/j.ajog.2013.08.008 · DOI · Paper page
- Jacoby, 2010, Racial and ethnic disparities in benign gynecologic conditions and associated surgeries, Am J Obstet Gynecol, 202, 514, 10.1016/j.ajog.2010.02.039 · DOI · Paper page
- Stewart, 2013, The burden of uterine fibroids for African-American women: results of a national survey, J Womens Health (Larchmt), 22, 807, 10.1089/jwh.2013.4334 · DOI · Paper page
- Elizalde, 1997, Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia, Transfusion (Paris), 37, 573, 10.1046/j.1537-2995.1997.37697335150.x · DOI
- Archer, 1999, Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group, Obstet Gynecol, 94, 323
- Di Carlo, 2005, Bleeding patterns during continuous estradiol with different sequential progestogens therapy, Menopause, 12, 520, 10.1097/01.gme.0000178450.29377.c9 · DOI
- Lethaby, 2001, Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids, Cochrane Database Syst Rev, CD000547
- Hornstein, 1998, Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study, Obstet Gynecol, 91, 16, 10.1016/S0029-7844(97)00620-0 · DOI · Paper page
- Derby, 2009, Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation, Am J Epidemiol, 169, 1352, 10.1093/aje/kwp043 · DOI · Paper page
Cited by
Epidemiology and management of uterine fibroids
Giuliani, E., As‐Sanie, S., & Marsh, E. E. (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13102 · Cited by 674
Elagolix: First global approval
Lamb, Y. N. (2018) · Drugs · doi:10.1007/s40265-018-0977-4 · Cited by 104
Shebley, M., Polepally, A. R., Nader, A., Ng, J. W., Winzenborg, I., Klein, C. E., Noertersheuser, P., Gibbs, M. A., & Mostafa, N. M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00840-7 · Cited by 68
Self-citationTaylor, H. S., Dun, E. C., & Chwalisz, K. (2019) · Pain Management · doi:10.2217/pmt-2019-0010 · Cited by 38
Metadata
- Authors
- Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R. A., Lukes, A. S., North, J. D., Soliman, A. M., Gao, J., Ng, J. W., & Chwalisz, K.
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 108
- Issue
- 1
- Pages
- 152-160.e4
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2195249017
- Cited by
- 81
- References
- 4
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 6 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. https://app.cochat.ai/papers/10.1016/j.fertnstert.2017.05.006
- The paper
- Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R. A., Lukes, A. S., North, J. D., Soliman, A. M., Gao, J., Ng, J. W., & Chwalisz, K. (2017). Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2017.05.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.